ArticleWorld journal of urology2023
Gut microbiome in men with chronic prostatitis/chronic pelvic pain syndrome: profiling and its predictive significance.
Article in World journal of urology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 16 citations in OpenAlex.
- The gut-prostate axis in benign prostatic diseases: Mechanistic pathways and therapeutic implications.iScience · 2026Review
- Review
- A Chinese expert consensus on prostate-pelvic syndrome.Current urology · 2026Article
- Unraveling the microbial landscape in prostate cancer: pathogenesis to therapy.NPJ biofilms and microbiomes · 2026Review
- Review
- Pathogen Detection and Diagnostic Scenarios in Chronic Prostatitis.Diagnostics (Basel, Switzerland) · 2025Article
- The role of microbiota in the chronic prostatitis/chronic pelvis pain syndrome: a review.Frontiers in microbiology · 2025Review
- Advancing prostate cancer treatment: the role of fecal microbiota transplantation as an adjuvant therapy.Current research in microbial sciences · 2025Review
- Causal effect of gut microbiota on the risk of prostatitis: a two-sample Mendelian randomization study.International urology and nephrology · 2024Article
- The Role and Applications of Artificial Intelligence in the Treatment of Chronic Pain.Current pain and headache reports · 2024Review
- Causality investigation among gut microbiota, immune cells, and prostate diseases: a Mendelian randomization study.Frontiers in microbiology · 2024Article
- Genetic insights into gut microbiota and risk of prostatitis: a Mendelian randomization study.Frontiers in microbiology · 2024Article
- Gut microbiome: a novel preventive and therapeutic target for prostatic disease.Frontiers in cellular and infection microbiology · 2024Review
- CP1Hao Decoction Alleviates Chronic Prostatitis by Modulating Arachidonic Acid Metabolism: A Multi-Omics Analysis.American journal of men's healthArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 5 institutions in 1 country.
Funding
Abstract
purposeTo investigate the difference in gut microbiome composition between patients with chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) and healthy controls, and to assess the potential of gut microbiota as predictive markers for CP/CPPS risk.
methodsThe present study included 41 CP/CPPS patients and 43 healthy controls in China. Fecal specimen data were obtained and analysed using 16S rRNA gene sequencing. Alpha and beta-diversity indices, relative microbiome abundances, cluster analysis, and linear discriminant analysis effect size (LEfSe) were employed. Microbial biomarkers were selected for the development of a diagnostic classification model, and the functional prediction was conducted using PICRUSt2.
resultsAlpha-diversity measures revealed no statistically significant difference in bacterial community structure between CP/CPPS patients and controls. However, significant differences were observed in the relative abundances of several bacterial genera. Beta-diversity analysis revealed a distinct separation between the two groups. Significant inter-group differences were noted at various taxonomic levels, with specific bacterial genera being significantly different in abundance. The LEfSe analysis indicated that three bacterial species were highly representative and seven bacterial species were low in CP/CPPS patients as compared to the control group. A diagnostic model for CP/CPPS based on microbial biomarkers exhibited good performance. PICRUSt2 functional profiling indicated significant differences in the development and regeneration pathway.
conclusionSignificant differences in the gut microbiome composition were found between groups. The study provided a novel diagnostic model for CP/CPPS based on microbiota, presenting promising potential for future therapeutic targets and non-invasive diagnostic biomarkers for CP/CPPS patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.